Multi-Attribute Method (MAM) review outlines technical principles and application strategies for biopharmaceutical quality control.
Background
Ensuring the quality and safety of biotechnological drugs, particularly complex therapeutic proteins like monoclonal antibodies, is paramount. Traditional quality control (QC) relies on a fragmented "single-attribute, single-method" approach, which can be inefficient and lack the depth needed to monitor all critical quality attributes (CQAs) comprehensively. This approach often falls short in precisely quantifying and dynamically tracking site-specific modifications that can impact drug efficacy and safety. There's a critical need for integrated analytical strategies that can simultaneously assess multiple attributes, thereby streamlining development, monitoring, and release processes.
Study Design
This review systematically summarized the technical principles, optimization strategies, and application progress of the Multi-Attribute Method (MAM). The authors integrated recent research cases involving complex therapeutic proteins, such as monoclonal antibodies and Fc fusion proteins, to illustrate MAM's practical utility. The review specifically focused on strategies and practical paths for workflow automation, new peak detection (NPD) optimization, the intact multi-attribute method (iMAM), and the integration of complementary technologies to enhance MAM's capabilities. The objective was to provide a valuable reference for the standardization and industrial application of MAM in biopharmaceutical quality control.
Results
The Multi-Attribute Method (MAM) is an integrated peptide mapping strategy based on liquid chromatography-mass spectrometry (LC-MS) technology, enabling precise quantification and dynamic tracking of multiple site-specific modifications in a single analysis. This significantly enhances the efficiency and depth of biopharmaceutical quality control. Its integrated application across process development, process monitoring, and product release has driven a paradigm shift from a "single-attribute, single-method" approach to a "multi-attribute, integrated-method" approach. Key advancements include strategies for workflow automation and NPD optimization, which improve the detection of unknown impurities. The review highlighted the utility of iMAM for analyzing intact proteins and the benefits of integrating complementary technologies. A significant regulatory milestone is the recent implementation of the United States Pharmacopeia (USP) General Chapter <1060>, which establishes the first official framework for MAM. This chapter provides crucial guidance for method validation and implementation, marking a substantial stride in regulatory acceptance. Future efforts are directed towards advancing automated platform development and creating intelligent data algorithms.
MAM enables precise quantification and dynamic tracking of multiple site-specific modifications in a single analysis, significantly enhancing biopharmaceutical quality control efficiency.
Key Findings
- MAM enables precise quantification and dynamic tracking of multiple site-specific modifications in a single analysis.
- The method drives a paradigm shift in biopharmaceutical QC from single-attribute to multi-attribute approaches.
- USP General Chapter <1060> establishes the first official regulatory framework for MAM.
- MAM's application extends across process development, monitoring, and product release for complex therapeutic proteins.
- Future efforts focus on advancing automated platforms and intelligent data algorithms for MAM.
Why It Matters
The Multi-Attribute Method (MAM) is poised to become a core analytical tool for biopharmaceutical quality control, offering enhanced efficiency and depth in monitoring critical quality attributes. For peptide users and biohackers involved in advanced compound analysis or quality assurance, understanding MAM's capabilities is crucial for assessing product integrity and consistency. This method standardizes the monitoring of complex protein modifications, potentially accelerating drug development timelines and ensuring higher product safety and efficacy. The establishment of USP General Chapter <1060> provides a foundational framework, guiding method validation and fostering broader industrial adoption. This advancement means that future biopharmaceutical products will likely undergo more rigorous and comprehensive quality assessments, leading to more reliable and safer compounds. The focus on automation and intelligent algorithms suggests a future where QC processes are faster, more accurate, and less labor-intensive, impacting how new peptides and biologics are brought to market.
multi-attribute method
mam
quality control
biopharmaceuticals
lc-ms
peptide mapping